FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2917684789> ?p ?o ?g. }

• W2917684789 abstract "Identifying and understanding potential drug-drug interactions (DDIs) are vital for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. This article discusses DDIs between doravirine, a nonnucleoside reverse transcriptase inhibitor (NNRTI), and cytochrome P450 3A (CYP3A) substrates and drugs that modulate CYP3A activity. Consistent with previously published in vitro data and DDI trials with the CYP3A substrates midazolam and atorvastatin, doravirine did not have any meaningful impact on the pharmacokinetics of the CYP3A substrates ethinyl estradiol and levonorgestrel. Coadministration of doravirine with CYP3A inhibitors (ritonavir or ketoconazole) increased doravirine exposure approximately 3-fold. However, these increases were not considered clinically meaningful. Conversely, previously published trials showed that coadministered CYP3A inducers (rifampin and rifabutin) decreased doravirine exposure by 88% and 50%, respectively (K. L. Yee, S. G. Khalilieh, R. I. Sanchez, R. Liu, et al., Clin Drug Investig 37:659-667, 2017 [https://doi.org/10.1007/s40261-017-0513-4]; S. G. Khalilieh, K. L. Yee, R. I. Sanchez, R. Liu, et al., J Clin Pharmacol 58:1044-1052, 2018 [https://doi.org/10.1002/jcph.1103]), while doravirine exposure following prior efavirenz administration led to an initial reduction in doravirine exposure of 62%, but the reduction became less pronounced with time (K. L. Yee, R. I. Sanchez, P. Auger, R. Liu, et al., Antimicrob Agents Chemother 61:e01757-16, 2017 [https://doi.org/10.1128/AAC.01757-16]). Overall, the coadministration of doravirine with CYP3A inhibitors and substrates is, therefore, supported by these data together with efficacy and safety data from clinical trials, while coadministration with strong CYP3A inducers, such as rifampin, cannot be recommended. Concomitant dosing with rifabutin (a CYP3A inducer less potent than rifampin) is acceptable if doravirine dosing is adjusted from once to twice daily; however, the effect of other moderate inducers on doravirine pharmacokinetics is unknown." @default.
• W2917684789 created "2019-03-02" @default.
• W2917684789 creator A5012406150 @default.
• W2917684789 creator A5038336871 @default.
• W2917684789 creator A5041695667 @default.
• W2917684789 creator A5044812776 @default.
• W2917684789 creator A5060337158 @default.
• W2917684789 creator A5062324491 @default.
• W2917684789 creator A5062480089 @default.
• W2917684789 creator A5070094735 @default.
• W2917684789 creator A5087795618 @default.
• W2917684789 creator A5087881684 @default.
• W2917684789 creator A5089247001 @default.
• W2917684789 date "2019-05-01" @default.
• W2917684789 modified "2023-10-16" @default.
• W2917684789 title "Doravirine and the Potential for CYP3A-Mediated Drug-Drug Interactions" @default.
• W2917684789 cites W1516986786 @default.
• W2917684789 cites W1979448806 @default.
• W2917684789 cites W1985971254 @default.
• W2917684789 cites W1986618988 @default.
• W2917684789 cites W1990308782 @default.
• W2917684789 cites W2000929966 @default.
• W2917684789 cites W2002176535 @default.
• W2917684789 cites W2005557760 @default.
• W2917684789 cites W2010427019 @default.
• W2917684789 cites W2015373829 @default.
• W2917684789 cites W2020276386 @default.
• W2917684789 cites W2029849864 @default.
• W2917684789 cites W2038704966 @default.
• W2917684789 cites W2040200721 @default.
• W2917684789 cites W2044015363 @default.
• W2917684789 cites W2044906812 @default.
• W2917684789 cites W2046137143 @default.
• W2917684789 cites W2055018724 @default.
• W2917684789 cites W2068946470 @default.
• W2917684789 cites W2090659780 @default.
• W2917684789 cites W2098705403 @default.
• W2917684789 cites W2100414335 @default.
• W2917684789 cites W2100669275 @default.
• W2917684789 cites W2102985344 @default.
• W2917684789 cites W2106737113 @default.
• W2917684789 cites W2109818488 @default.
• W2917684789 cites W2110083669 @default.
• W2917684789 cites W2119955031 @default.
• W2917684789 cites W2120512985 @default.
• W2917684789 cites W2128175762 @default.
• W2917684789 cites W2147472643 @default.
• W2917684789 cites W2148241768 @default.
• W2917684789 cites W2149383871 @default.
• W2917684789 cites W2158298030 @default.
• W2917684789 cites W2242706280 @default.
• W2917684789 cites W2256825639 @default.
• W2917684789 cites W2308863118 @default.
• W2917684789 cites W2327696366 @default.
• W2917684789 cites W2390017674 @default.
• W2917684789 cites W2416139320 @default.
• W2917684789 cites W2469941867 @default.
• W2917684789 cites W2528141927 @default.
• W2917684789 cites W2550942625 @default.
• W2917684789 cites W2551398029 @default.
• W2917684789 cites W2569163824 @default.
• W2917684789 cites W2588335835 @default.
• W2917684789 cites W2601464367 @default.
• W2917684789 cites W2601741382 @default.
• W2917684789 cites W2614048460 @default.
• W2917684789 cites W2740199405 @default.
• W2917684789 cites W2742578179 @default.
• W2917684789 cites W2745713480 @default.
• W2917684789 cites W2789289526 @default.
• W2917684789 cites W2792742326 @default.
• W2917684789 cites W2800224917 @default.
• W2917684789 cites W2887073112 @default.
• W2917684789 cites W2889157553 @default.
• W2917684789 cites W2912979025 @default.
• W2917684789 cites W2938502016 @default.
• W2917684789 cites W646865264 @default.
• W2917684789 doi "https://doi.org/10.1128/aac.02016-18" @default.
• W2917684789 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6496093" @default.
• W2917684789 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30783000" @default.
• W2917684789 hasPublicationYear "2019" @default.
• W2917684789 type Work @default.
• W2917684789 sameAs 2917684789 @default.
• W2917684789 citedByCount "20" @default.
• W2917684789 countsByYear W29176847892019 @default.
• W2917684789 countsByYear W29176847892020 @default.
• W2917684789 countsByYear W29176847892021 @default.
• W2917684789 countsByYear W29176847892022 @default.
• W2917684789 countsByYear W29176847892023 @default.
• W2917684789 crossrefType "journal-article" @default.
• W2917684789 hasAuthorship W2917684789A5012406150 @default.
• W2917684789 hasAuthorship W2917684789A5038336871 @default.
• W2917684789 hasAuthorship W2917684789A5041695667 @default.
• W2917684789 hasAuthorship W2917684789A5044812776 @default.
• W2917684789 hasAuthorship W2917684789A5060337158 @default.
• W2917684789 hasAuthorship W2917684789A5062324491 @default.
• W2917684789 hasAuthorship W2917684789A5062480089 @default.
• W2917684789 hasAuthorship W2917684789A5070094735 @default.
• W2917684789 hasAuthorship W2917684789A5087795618 @default.
• W2917684789 hasAuthorship W2917684789A5087881684 @default.
• W2917684789 hasAuthorship W2917684789A5089247001 @default.

• next